A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

BACKGROUND: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL). M...

Descripción completa

Detalles Bibliográficos
Autores principales: Younes, A, Vose, J M, Zelenetz, A D, Smith, M R, Burris, H A, Ansell, S M, Klein, J, Halpern, W, Miceli, R, Kumm, E, Fox, N L, Czuczman, M S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008610/
https://www.ncbi.nlm.nih.gov/pubmed/21081929
http://dx.doi.org/10.1038/sj.bjc.6605987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008610/
https://www.ncbi.nlm.nih.gov/pubmed/21081929
http://dx.doi.org/10.1038/sj.bjc.6605987

Ejemplares similares